Amarin Corp Plc (AMRN)

[couldbebetter]

Even if REDUCE-IT results are outstanding, the FDA could still delay any new indication approvals sought or could argue that the mineral oil placebo had skewed the results. The FDA is the unknown risk here, not the medications effectiveness. The other problem is that although the potential market is vast, only big-pharma has the resources to exploit it. Right now every doctor I have asked about Vascepa did not have a clue...one did not even know what EPA is. I am invested until a buyout or bankruptcy. DO NOT BUY MORE UNLESS YOU CAN AFFORD A TOTAL LOSS. That being said I believe that if things go well we could see over 20 or even 30 if no further dilution occurs. This medication has such great potential for so many indications...what a shame that those are not being explored right now.